Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,059,007 papers from all fields of science
Search
Sign In
Create Free Account
pirozadil
Known as:
2,6-pyridinediyldimethylene bis(3,4,5-trimethoxybenzoate)
A nicotinic acid derivative with antilipidemic activity.
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Pyridines
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
1989
1989
Treatment of Diet‐Resistant Polygenic Hypercholesterolaemic Patients with a New Nicotinate Derivative; In Vivo and In Vitro Low Density Lipoprotein Metabolic Studies
L. Masana
,
A. Escobar
,
+4 authors
P. Turner
Journal of clinical pharmacology
1989
Corpus ID: 20826165
Six patients (four women and two men) with mild to moderate hypercholesterolemia, but with no clinical evidence of the disease…
Expand
1989
1989
[Clinical evaluation of pirozadil, administered continuously over four and a half years, in patients with hyperlipoproteinemia type IIa].
C. Cuchi de la Cuesta
,
M. T. Cuchi Alfaro
,
C. Cuchí Alfaro
Revista clínica española (Ed. impresa)
1989
Corpus ID: 32236255
With the goal to evaluate the long term efficacy and tolerance of pirozadil, 20 patients with hypercholesterolemia (type II a…
Expand
1989
1989
[Clinical evaluation of pirozadil, administered continuously over four and a half years, in patients with hyperlipoproteinemia type IIa].
C. CuchídelaCuesta
,
Cuchi Alfaro Mt
,
C. CuchiAlfaro
1989
Corpus ID: 77596849
Abstract With the goal to evaluate the long term efficacy and tolerance of pirozadil, 20 patients with hypercholesterolemia (type…
Expand
1987
1987
The effect of pirozadil on plasma lipids and lipoproteins in 1185 hyperlipidaemic subjects. Multicentre study in general practice in Spain.
R. Tapounet
,
I. Marti Ragué
Drugs under experimental and clinical research
1987
Corpus ID: 46000587
The lipid-lowering agent pirozadil was tested in 1185 hyperlipidaemic subjects during a 2-4 months' intake. Plasma triglycerides…
Expand
1987
1987
Effect of pirozadil on lipids, lipoproteins and apolipoproteins in Japanese with type IIa hyperlipoproteinemia.
M. Shinomiya
,
Y. Ishikawa
,
K. Shirai
,
Y. Saito
,
S. Yoshida
Arzneimittel-Forschung
1987
Corpus ID: 41787988
Pirozadil (pyridine 2,6-dimethanol-bis(3,4,5-trimethoxybenzoate), Pemix) was administered for 16 weeks at a dose of 1.5 or 2.0 g…
Expand
1987
1987
[Efficacy and tolerance to pirozadil over a long term. Drug surveillance study. The Pirozadil Drug Surveillance Group].
Medicina clínica (Ed. impresa)
1987
Corpus ID: 8548937
1982
1982
[Single-blind study of the efficacy of pirozadil versus alufibrate in the treatment of primary hyperlipoproteinemias].
J. H. Honorato Pérez
,
J. A. Azanza Perea
Revista de medicina de la Universidad de Navarra
1982
Corpus ID: 41379491
Pirozadil and alufibrate are compared by a single-blind study over two groups 20 patients with primary hyperlipoproteinemia…
Expand
1982
1982
[Clinical pharmacology of pirozadil].
J. Pedraz de Cabo
Revista clínica española (Ed. impresa)
1982
Corpus ID: 45750283
1978
1978
Efficacy of hypolipidemic treatment in inhibition of experimental atherosclerosis: the effect of nicotinic acid and related compounds.
M. Parwaresch
,
H. Haacke
,
C. Mäder
Atherosclerosis
1978
Corpus ID: 25807018
1977
1977
[Effects of pirozadil on metabolic blood flow in brain rabbit (author's transl)].
J. Balasch
,
L. Palacios
Archivos de farmacologia y toxicologia
1977
Corpus ID: 31471746
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE